Bayer/Onyx 43-9006 in Phase III for HCC
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer/Onyx are starting a Phase III study of their oral RAF kinase/VEGF inhibitor 43-9006 (sorafenib) for use as monotherapy in advanced hepatocellular carcinoma, the firms say March 8. Five hundred patients without prior systemic treatment will be randomized in the double-blind, placebo-controlled trial; overall survival, time to symptom progression and time to tumor progression will be assessed. Median survival was 9.2 months and median time to progression was 4.2 months in a Phase II HCC trial. Bayer/Onyx originally planned to submit 43-9006 for renal cell carcinoma based on Phase II data, but are now waiting for results from an 800-patient Phase III study (1Pharmaceutical Approvals Monthly November 2004, p. 35). Both Phase III trials received special protocol assessments from FDA...
You may also be interested in...
Bayer/Onyx sorafenib accepted into Pilot 1
Bayer/Onyx' oncologic sorafenib (formerly BAY 43-9006) is accepted into FDA's continuous marketing application Pilot 1 program, the firms announce May 4. The acceptance pertains to the dual RAF kinase/VEGF inhibitor's use in renal cell carcinoma. Bayer/Onyx said an NDA is "in the preparation stages"; the sponsors continue to project a first-half 2006 approval for metastatic RCC. A separate Phase III clinical program in hepatocellular carcinoma began in March (1Pharmaceutical Approvals Monthly March 2005, In Brief)...
Bayer/Onyx will wait for kidney oncologic Phase III data
Bayer/Onyx plan to wait for Phase III overall survival results for their kidney cancer agent BAY 43-9006 instead of moving forward with submission using Phase II data, which will push launch projections back to 2006. Bayer outlined a plan to file based on the Phase II results when the data was presented at the American Society of Clinical Oncology meeting in June. The firms expect to enroll 800 renal cell carcinoma patients in the Phase III trial of the RAF kinase inhibitor, now underway. The trial "was initiated after a special protocol assessment was completed by the FDA in the fourth quarter of 2003," Onyx says Oct. 25...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.